Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $70,988.94 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the sale, the chief executive officer directly owned 618,996 shares in the company, valued at approximately $3,998,714.16. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kevin Lee also recently made the following trade(s):

• On Friday, January 2nd, Kevin Lee sold 10,325 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.80, for a total value of $70,210.00.

Bicycle Therapeutics Trading Down 0.6%

BCYC traded down $0.04 during trading hours on Tuesday, hitting $6.57. The company’s stock had a trading volume of 259,093 shares, compared to its average volume of 215,285. The company has a 50-day simple moving average of $6.97 and a 200 day simple moving average of $7.42. The firm has a market capitalization of $455.76 million, a PE ratio of -1.81 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.03 and a fifty-two week high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. The company had revenue of $11.73 million during the quarter, compared to analyst estimates of $8.25 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%. Research analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCYC has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They issued a “hold” rating and a $10.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.73.

Institutional Trading of Bicycle Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Assetmark Inc. lifted its position in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after acquiring an additional 1,552 shares during the last quarter. Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $70,000. Sei Investments Co. purchased a new stake in shares of Bicycle Therapeutics during the second quarter valued at $74,000. Virtus Investment Advisers LLC lifted its holdings in shares of Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock valued at $75,000 after purchasing an additional 2,659 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $86,000. 86.15% of the stock is currently owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.